Research & Development
Learn more about our herbal and medicinal product process. Bringing the results from the laboratory to market.
Research & Development
Our herbal medicinal product, WAHI-101, successfully targets SARS-CoV-2 in several ways, thereby hindering its infectivity and pathogenesis.
Also, our product, WAHI-102, modulates inflammatory cytokines and regulates their production, thus lowering the inflammatory process in many inflammatory and autoimmune diseases.
Market Ready Supplement
| Antiviral | Autoimmune Disease |
|---|---|
|
|
Research and Development
| Nootropics | Fertility | Cancer |
|---|---|---|
|
|
|
Our Studies
Research studies have shown that RECOCOVTM supplement ingredients inhibit SARS-CoV-2 (COVID-19) from binding to ACE-2 receptors (the receptor that facilitates viral entry into lung cells) and block specific enzymes needed for SARS-CoV-2 replication*
In addition, RECOCOVTM has been shown to modulate pro-inflammatory cytokines, thereby reducing the risk of cytokine storm in sepsis.
* This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.